Recent Quotes
My Watchlist
Indicators
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

48.73 -1.21 (-2.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,168,574
Open 49.44
Bid (Size) 45.40 (100)
Ask (Size) 52.61 (100)
Prev. Close 49.94
Today's Range 47.95 - 49.75
52wk Range 22.61 - 50.71
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire

Performance

YTD
+15.0%
+15.0%
1 Month
+20.6%
+20.6%
3 Month
+46.0%
+46.0%
6 Month
+9.9%
+9.9%
1 Year
+75.0%
+75.0%

More News

Read More
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price ↗
Via Chartmill
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Veracyte Inc (NASDAQ:VCYT): A High-Growth Biotech Stock Poised for a Technical Breakout ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate ↗
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Posts Strong Q4 Earnings Beat and Positive 2026 Outlook ↗
Via Chartmill
Topics Earnings
Veracyte Inc (NASDAQ:VCYT): A Prime GARP Stock with Strong Growth and a Sound Balance Sheet ↗
Via Chartmill
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
From USA News Group
Via GlobeNewswire
News headline image
Why Veracyte Stock Is Skyrocketing Higher This Week ↗
Via The Motley Fool
News headline image
Veracyte (VCYT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Veracyte Announces First Quarter 2026 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
From Veracyte, Inc.
Via Business Wire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Names Kevin Haas as Chief Development and Technology Officer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte (VCYT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
From Veracyte
Via Business Wire

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 48.73
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 06/05/26 04:00 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 3.29B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>